Abstract:The natural product‐enriched DNA‐encoded library (nDEL) approach, merging natural products with DEL, is applied in a reverse pharmacology study targeting tumor necrosis factor α (TNF‐α), a key cytokine in inflammation. Several natural products, particularly kaempferol, a flavonoid, has been identified to recognize and attenuate the TNF‐α signaling in cells as that of adalimumab, and reduce 12‐O‐tetradecanoylphorbol‐13‐acetate‐induced ear inflammation in mice. Tumor necrosis factor α (TNF‐α) inhibitors have shown great success in the treatment of autoimmune diseases. However, to date, approved drugs targeting TNF‐α are restricted to biological macromolecules, largely due to the difficulties in using small molecules for pharmaceutical intervention of protein–protein interactions. Herein the power of a natural product‐enriched DNA‐encoded library (nDEL) is exploited to identify small molecules that interfere with the protein–protein interaction between TNF‐α and the cognate receptor. Initially, to select molecules capable of binding to TNF‐α , "late‐stage" DNA modification method is applied to construct an nDEL library consisted of 400 sterically diverse natural products and pharmaceutically active chemicals. Several natural products, including kaempferol, identified not only show direct interaction with TNF‐α, but also lead to the blockage of TNF‐α/TNFR1 interaction. Significantly, kaempferol attenuates the TNF‐α signaling in cells and reduces the 12‐O‐tetradecanoylphorbol‐13‐acetateinduced ear inflammation in mice. Structure‐activity‐relationship analyses demonstrate the importance of substitution groups at C‐3, C‐7, and C‐4' of kaempferol. The nDEL hit, kaempferol, represents a novel chemical scaffold capable of specifically recognizing TNF‐α and blocking its signal transduction, a promising starting point for the development of a small molecule TNF‐α inhibitor for use in the clinical setting.

Discovery of Highly Potent Tnf Alpha Inhibitors Using Virtual Screen

Discovery of Highly Potent TNFα Inhibitors Using Virtual Screen.

Discovery of Novel Ligands for TNF-α and TNF Receptor-1 Through Structure-Based Virtual Screening and Biological Assay

Discovery of an Orally Active Small-Molecule Tumor Necrosis Factor-α Inhibitor

Discovery of an Orally Active Small Molecule TNF-α Inhibitor.

Design, Synthesis, and Evaluation of Dihydrobenzo[ cd ]indole-6-sulfonamide as TNF-α Inhibitors.

Discovery of Anorally Active Small-Molecule TumorNecrosis Factor‑α Inhibitor

Ligand-based pharmacophore modeling of TNF-α to design novel inhibitors using virtual screening and molecular dynamics

Discovery of Cyclic Peptide Inhibitors Targeted on TNFα-TNFR1 from Computational Design and Bioactivity Verification

Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer

A Small Molecule Selected from a DNA‐Encoded Library of Natural Products That Binds to TNF‐α and Attenuates Inflammation In Vivo

Deep learning based predictive modeling to screen natural compounds against TNF-alpha for the potential management of Rheumatoid Arthritis: Virtual screening to comprehensive in silico investigation

Discovery of binding proteins for a protein target using protein-protein docking-based virtual screening.

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

Tiamulin Inhibits TNF-α and Alleviates Psoriasis-Like Dermatitis.

Targeting Tumor Necrosis Factor Receptor 1 with Selected Aptamers for Anti-Inflammatory Activity

Identification of Novel Tyrosinase Inhibitors with Nanomolar Potency Using Virtual Screening Approaches

Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

Discovery of 4-Aminoquinoline-3-carboxamide Derivatives As Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis

Novel peptide inhibitor of human tumor necrosis factor-α has antiarthritic activity

Virtual High-Throughput Screening To Identify Novel Activin Antagonists